Quantum BioPharma QNTM 深 滬
等待開盤 09-17 09:30:00 美东时间
3.65
+0.190
+5.49%
華盛通- 最 高3.69
- 今 開3.48
- 成交量 20.02万股
- 最 低 3.3863
- 昨 收 3.46
- 總市值 2951.93万
- 52周最高 19.30
- 市盈率 靜 --
- 換手率 2.48%
- 52周最低 2.07
- 委 比 60.00%
- 總股本 808.75万
- 歷史最高 910.00
- 量 比 0.86
- 振 幅 8.78%
- 歷史最低 2.07
- 每 手 1
- 風險率 4.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
Quantum BioPharma Ltd. (NASDAQ: QNTM) has received FDA clearance to launch a phase 2 trial for Lucid-MS, a first-in-class drug designed to protect and potentially rebuild the myelin sheath in multiple sclerosis patients. This marks the first time a drug targeting this mechanism will be tested in humans, addressing a critical gap in MS treatment options. Lucid-MS aims to prevent and reverse myelin degradation, offering hope to nearly 1 million peo...
09-11 12:30
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
Rodman & Renshaw Initiates Coverage On Quantum BioPharma with Buy Rating, Announces Price Target of $8
Rodman & Renshaw analyst Michael King initiates coverage on Quantum BioPharma (NASDAQ:QNTM) with a Buy rating and announces Price Target of $8.
09-01 01:00
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential
Austin, Texas, United States, August 31st, 2026, FinanceWire Disseminated...
09-01 00:30
Quantum Biopharma Provides Corporate Update
Quantum BioPharma Ltd. has granted 572,500 stock options to directors, officers, employees, and consultants. Each option is exercisable at C$4.80 for five years, with 172,500 vesting immediately and 400,000 subject to performance-based vesting. The options are subject to a four-month and one-day hold period and were granted under the Company's equity incentive plan. Quantum focuses on developing innovative biotech solutions for neurodegenerative,...
08-21 23:00
Quantum BioPharma Submits IND Application To FDA For Lucid-21-302, Its New Drug Candidate For Treatment Of Multiple Sclerosis
Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today
04-01 20:09
Quantum BioPharma Q4 EPS $(0.71) Beats $(0.93) Estimate
Quantum BioPharma (NASDAQ:QNTM) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.93) by 23.66 percent. This is a 65.53 percent increase over losses of $(2.06) per share from
03-27 05:58
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers ENvue Medical (NASDAQ:FEED) shares increased by 59.4% to $2.28 during T...
03-25 01:05
Quantum BioPharma Publishes Data From Clinical Study Of NCT06505239 Of Its Dietary Supplement Product Unbuzzd To Evaluate Impacts Of Unbuzzd On Alcohol Intoxication, Alcohol Metabolism
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions,
03-23 20:28
Reported On March 11: Quantum BioPharma Provides Corporate Update; Announces That Further To Its News Release On March 10, 2026, The Company Has Revised The Terms Of The Debenture Units; Reduce The Conversion Price Per Share To $3.00; Increase The Number Of Warrants Included As Part Of Each Debenture Unit To 333.33; Reduce The Exercise Price Per Warrant Share To $3.75
https://www.globenewswire.com/news-release/2026/03/11/3254229/0/en/Quantum-BioPharma-Provides-Corporate-Update.html
03-12 22:19
